BRCA1 and breast carcinoma: Finally, the cytotoxicity of olaparib against the BRCA1-deficient MDA-MB-436 breast cancer cells [48] was further significantly enhanced by 2 and 4 μM ATL (Fig. S4D), suggesting that ATL sensitized cancer cells to olaparib through mechanisms other than inducing HR deficiency.